Newsroom

Industry News

18 Jan

Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer

NEW YORK, Jan. 18, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced that Dr. Mark Berger has been appointed Chief Medical Officer effective today. Dr. Berger joins Actinium with significant...

Read more

18 Jan

Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto® (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting

ENGLEWOOD, Colo., Jan. 18, 2017 /PRNewswire/ — Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that two posters demonstrating clinical data for Natesto® (testosterone) Nasal Gel were accepted for presentation at the American Urological Association 2017...

Read more

18 Jan

Protea Extends Collaboration with Protein Metrics

MORGANTOWN, W.Va., Jan. 18, 2017 (GLOBE NEWSWIRE) — Protea Biosciences Group, Inc. (PRGB) (“Protea”) announced today that the Company has signed a renewal of its collaboration with California-based Protein Metrics Inc. for further applications development of their advanced analytical software for Protea’s molecular information services. “By combining our high-resolution...

Read more

18 Jan

MTBC in 2016 — An Exciting Year in Review

SOMERSET, NJ–(Marketwired – Jan 18, 2017) –  MTBC ( NASDAQ : MTBC ), a leading provider of proprietary, cloud-based electronic health records, practice management and mHealth solutions, is pleased to issue an in-depth year-end review of corporate accomplishments for 2016, as well as offer an outlook for what the...

Read more

17 Jan

NABUFIT to participate as a sponsor for the 9th Annual Big Brothers Big Sisters of NYC PONG Tournament of Champions Charity Event

NEW YORK, Jan. 17, 2017 (GLOBE NEWSWIRE) — NABUFIT Global Inc. (NBFT), developer of a ground breaking new training portal that enhances individual workouts by providing expert advice from professional trainers, health experts and international sports stars, today announced that it will be sponsoring the 9th Annual Big Brothers Big Sisters...

Read more

17 Jan

Ascent Solar and EnerPlex Exhibit at the 2017 CES Trade Show

THORNTON, CO–(Marketwired – Jan 17, 2017) – Ascent Solar Technologies, Inc. ( OTCQB : ASTI ), a developer and manufacturer of state-of-the-art, lightweight, and flexible thin-film photovoltaic (PV) solutions, announced today that the Company’s EnerPlex™ brand was once again, well received at the 2017 International Consumer Electronics Show (CES)...

Read more

17 Jan

Check-Cap Enrolls First Patient in Clinical Trial to Support CE Mark of Its C-Scan® Colorectal Cancer Screening System

ISFIYA, Israel, January 17, 2017 /PRNewswire/ — Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company developing a capsule-based system for preparation-free, colorectal cancer (CRC) screening, today announced the enrollment of the first patient in its multi-center study of the C-Scan® system in...

Read more

17 Jan

BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

TEL AVIV, Israel, January 17, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients...

Read more

17 Jan

Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients

LAWRENCEVILLE, N.J., Jan. 17, 2017 (GLOBE NEWSWIRE) — Celsion Corporation (CLSN) today announced data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with...

Read more

Page 20 of 227« First...10...1819202122...304050...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address